<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048304</url>
  </required_header>
  <id_info>
    <org_study_id>SASI</org_study_id>
    <nct_id>NCT04048304</nct_id>
  </id_info>
  <brief_title>Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial</brief_title>
  <official_title>Short Post-surgical Antibiotic Therapy in Spine Infections - a Pro-spective, Randomized, Unblinded, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balgrist University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We implement a prospective, randomized, unblinded, non-inferiority trial regarding the
      duration of systemic, targeted antibiotic therapy after the first surgical debridement for
      spine infection; randomizing 1:1 between

        1. Six and twelve weeks of antibiotic therapy if there is an implant left in place

        2. Three and six weeks of antibiotic therapy if there is no implant left
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of infection at 12 months after treatment</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>no clinical and microbiological recurrences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>costs</measure>
    <time_frame>up to 12 months</time_frame>
    <description>total costs for treatment of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of sick leave</measure>
    <time_frame>up to 12 months</time_frame>
    <description>duration of sick leave for treatment of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>up to 12 months</time_frame>
    <description>number of days of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>short antibiotic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long antibiotic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duration of standard antibiotic therapy</intervention_name>
    <description>antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.</description>
    <arm_group_label>long antibiotic therapy</arm_group_label>
    <arm_group_label>short antibiotic therapy</arm_group_label>
    <other_name>Co-amoxiclav, vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spine surgery and intraoperative debridement with any technique

          -  At least 12 months of scheduled follow-up from hospitalization

          -  Bacterial spine infection of any nature, independently of implants or co-morbidities

        Exclusion Criteria:

          -  Mycobacterial, fungal, nocardial, and Actinomyces infections in the spine

          -  Non-resected cancer in the infection site

          -  Bone marrow or recent solid organ transplant patient (Recent: &lt;5 years)

          -  Any other infection in the patient requiring more than 6 weeks of antibiotic therapy

          -  More than three intraoperative debridements performed for spine infection

          -  Absence of at least one surgical intraoperative debridement of infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilker Uckay, PD Dr med</last_name>
    <role>Study Director</role>
    <affiliation>Balgrist University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilker Uckay, PD Dr med</last_name>
    <phone>+41 44 386 1111</phone>
    <email>ilker.uckay@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Betz, PD Dr med</last_name>
    <phone>+41 44 386 1111</phone>
    <email>michael.betz@balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Balgrist University Hospital</name>
      <address>
        <city>ZÃ¼rich</city>
        <state>Zurich</state>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilker Uckay, MD</last_name>
      <phone>+41 44 386 37 05</phone>
      <email>ilker.uckay@balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Regula Schupbach</last_name>
      <phone>+41 44 510 73 75</phone>
      <email>regula.schuepbach@balgrist.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>identifying IPD will not be shared with other Researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

